AbbVie Inc ABBV
Stock research in plain language · As of Oct 04, 2026 · updated once a week, after the trading week closes
What the company does
AbbVie Inc is a mega-cap company in the Healthcare sector (Drug Manufacturers - General), with a market value of $464.4B, based in the USA.
It employs about 57,000 people and has been listed since Jan 02, 2013.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.
Cheap or expensive? relatively expensive
Its price-to-earnings (P/E) is 74.2 versus 34.2 for 4 direct peers — relatively expensive.
Revenue is growing 10% versus the same quarter last year.
On analysts' next-year forecasts the multiple drops to 16.4 — they expect higher earnings.
The average analyst price target is 278.86, 6% above the current price (their view, not ours).
The stock sits at 92% of its one-year range (0% = the low, 100% = the high).
The risks
- No risk flags were detected from the data we have.
Strengths
- ✅ Profitable — 21 of every 100 dollars of revenue stays as profit.
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Most analysts rate it buy (24 vs 1).
- ✅ Pays a dividend (2.6% a year).
What changed this week
Over the past week the stock fell 0.6% (for comparison: S&P 500 -0.2%, sector ETF XLV -2.6%).
This week's news
- AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy? finance.yahoo.com · 2026-10-04
- AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot seekingalpha.com · 2026-10-03
- How to Create a Million-Dollar Stock Portfolio finance.yahoo.com · 2026-10-02
- Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise? finance.yahoo.com · 2026-10-02
- J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to Watch finance.yahoo.com · 2026-10-02
- AbbVie (ABBV) Stock May Be 41% Undervalued Following JUVMO Approval finance.yahoo.com · 2026-10-01
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group.